Phage Cocktail-SPK in Second Degree Burn Wounds

Phase 1, randomised, open-label trial of phage cocktail-SPK in Wound infection (WI) (2 arms), sponsored by Precisio Biotix Therapeutics. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 14 days and Incidence of treatment discontinuation due to adverse events at 14 days. Status: unknown.